UBS analyst Eliana Merle reiterated a Neutral rating and $115.00 price target on BioNTech (NASDAQ: BNTX).The analyst commented, "Ivo (PD1/VEGF) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE